MAYBAKER logo

May & Baker Nigeria plc Stock Price

NGSE:MAYBAKER Community·₦65.6b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 28 Fair Values set on narratives written by author

MAYBAKER Share Price Performance

₦38.00
19.80 (108.79%)
₦38.00
19.80 (108.79%)
Price ₦38.00

MAYBAKER Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Outstanding track record with flawless balance sheet.

1 Risk
2 Rewards

May & Baker Nigeria plc Key Details

₦37.2b

Revenue

₦24.7b

Cost of Revenue

₦12.5b

Gross Profit

₦7.9b

Other Expenses

₦4.6b

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
2.65
33.54%
12.29%
27.9%
View Full Analysis

About MAYBAKER

Founded
1944
Employees
414
CEO
Patrick Ajah
WebsiteView website
may-baker.com

May & Baker Nigeria Plc, together with its subsidiaries, manufactures, sells, and distributes human pharmaceuticals, human vaccines, and consumer products in Nigeria. It operates through Pharmaceuticals and Beverage segments. The company offers pharmaceuticals, including anti-diabetic, anti-hypersensitive, anti-infective, anti-malaria, analgesic, cough and cold, and anxiolytics; and nature care products. It also provides beverage drinks, including bottled water under the Lily Water name; and hand and surface sanitizers under the Smartans name. In addition, the company engages in contract manufacturing of pharmaceutical products; and in healthcare and industrial packaging. May & Baker Nigeria Plc was incorporated in 1944 and is headquartered in Lagos, Nigeria.

Recent MAYBAKER News & Updates

Narrative Update Jul 09

May & Baker Nigeria Plc Delivers Strong Earnings Growth in Q1 2026 Driven by Revenue Expansion and Margin Recovery

Executive Summary Analyst: Qudus Adebara (Research Analyst, DLM Capital Group) May & Baker Nigeria Plc posted a strong financial performance for the three months ended March 31, 2026, supported by robust revenue growth, improved operating leverage, and higher profitability across its pharmaceutical segment. Group revenue rose by 12% YoY to ₦8.40 billion, driven primarily by strong pharmaceutical sales.

Recent updates

No updates

May & Baker Nigeria plc Competitors